Atlas Trials

The Central Hospital of Lishui City

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch The Central Hospital of Lishui City

RecordFirmDate
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NCT06792786)The Central Hospital of Lishui City2024-12-10
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC (NCT06364046)The Central Hospital of Lishui City2024-04-01
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure (NCT05248022)The Central Hospital of Lishui City2024-02-01
Immunotherapy After Radiotherapy in Elderly ESCC (NCT05791136)The Central Hospital of Lishui City2023-04-01
Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer (NCT05519202)The Central Hospital of Lishui City2022-08-31
Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer (NCT05278754)The Central Hospital of Lishui City2022-03-12
Independent Risk Factors Analysis and Model Construction For Recurrence After Radiofrequency/Microwave Ablation of Colorectal Cancer With Liver Metastases: a Retrospective, Multicenter Trial (NCT05268549)The Central Hospital of Lishui City2022-03-12
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma (NCT05247996)The Central Hospital of Lishui City2022-03-01
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure (NCT05233358)The Central Hospital of Lishui City2022-02-01
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (NCT04776187)The Central Hospital of Lishui City2021-03-01

Track The Central Hospital of Lishui City automatically

Every clearance here is in the API, with alerts when new ones post.